Pharmacometric-Based Evaluation of Salmeterol and Its Metabolite α-Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control.

ABSTRACT: Salmeterol is a commonly used β₂-agonist included on the List of Prohibited Substances and Methods published by the World Anti-Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α-hydroxysalmeterol, in plasma and urine after inhalation. The model was used to evaluate the ability of the current minimum reporting level (MRL) of 10 ng/mL for salmeterol to discriminate between permitted and prohibited use of salmeterol. Six studies on healthy participants, chronic asthmatics, or athletes were pooled and provided a total of 1175 concentrations (275 and 398 for salmeterol and 185 and 317 for α-hydroxysalmeterol in plasma and urine, respectively) from 92 individuals. A two-compartment model assu

SUBMITTER: Thoueille P 

PROVIDER: S-EPMC12823318 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature